Evidence map›Paper›PMID 41073764›Full record

ReviewEuropean journal of pediatrics2025

Interpreting liver function markers in children on continuous renal replacement therapy for acute liver failure.

Wun Fung Hui, Akash Deep

Abstract readReview
In one paragraph

Review in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Wun Fung HuiPaediatric Intensive Care Unit, King's College Hospital NHS Foundation Trust, London, UK.
Akash DeepPaediatric Intensive Care Unit, King's College Hospital NHS Foundation Trust, London, UK. akash.deep@nhs.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Children with acute liver failure (ALF) often experience hyperammonaemia, fluid overload, metabolic derangements, and multi-organ failure. Continuous renal replacement therapy (CRRT) is commonly used for renal and non-renal indications, particularly in those with hyperammonaemia and hepatic encephalopathy. However, the non-selective nature of CRRT can result in the clearance of beneficial metabolites and liver-related biomarkers, which are important for monitoring disease progression or improvement. Therefore, understanding the kinetic principles governing molecular clearance during CRRT is crucial for accurate interpretation of liver biochemistry to inform clinical decision-making. By considering the kinetic properties of hepatic markers, including bilirubin, bile acids, liver enzymes, metabolites, waste products, inflammatory markers, albumin, and coagulation proteins, we describe the impact of CRRT on the plasma levels of these markers. In addition, we discuss various CRRT attributes, and the removal of these markers is also discussed. Metabolites and waste products, including ammonia, lactate, and urea, are the most useful markers to inform CRRT responsiveness, owing to their small molecular size, low degree of protein binding, and small volume of distribution; whereas bilirubin, bile acids, coagulation factors, and albumin remain true indicators of hepatic function and clinical condition. It should be noted that the overall plasma levels of any molecules reflect the balance between production and clearance, even for molecules with a high degree of CRRT removal. Awareness of these properties helps clinicians differentiate dialytic response versus genuine hepatic recovery or deterioration, guiding a more rational interpretation of clinical progression in ALF with liver transplant/spontaneous native recovery or mortality as the outcomes.Conclusion: Understanding the kinetic behaviour of liver-related markers during CRRT is essential to distinguish between dialytic clearance and true changes in hepatic function. This knowledge enables more accurate clinical interpretation, guiding decision-making in children with acute liver failure and optimizing management strategies toward recovery or timely transplantation.

Indexed as

Continuous Renal Replacement TherapyLiverLiver Failure, AcuteBiomarkersChildHumansLiver Function TestsBiomarkersAcute liver failureChildrenContinuous renal replacement therapyHepatic markersIntensive careKinetics

Identifiers

PMID41073764
PMCPMC12513971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.